Guidance warns against using 2 phthalates as drug excipient

03/27/2012 | InPharm.com

The FDA said in draft guidance that drugmakers should avoid using dibutyl phthalate and di(2-ethylhexyl) phthalate as an excipient in pharmaceutical and biologic products because they could be toxic to humans. The agency's Inactive Ingredients Database lists possible alternatives to the two phthalates.

View Full Article in:

InPharm.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC